For the Inventor, By the Inventor

Enter assignee name

Ipca Laboratories Limited

USPTO Granted Patents = 17

% Expired Patents = 88.2

CIPO Patents = 2

EPO Patents = 3

Forward Citations = 11

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Ashok Kumar (16 out of 17 patents)

Dharmendra Singh (7 out of 7 patents)

Satish Rajanikant Soudagar (5 out of 6 patents)

4. Nellithanath Thankachen Byju (5 out of 5 patents)

5. Gaurav Sahal (3 out of 3 patents)

6. Ganesh Devidas Mahale (3 out of 3 patents)

7. Nalinakshya Balaram Panda (3 out of 3 patents)

8. Arpana Prashant Mathur (2 out of 2 patents)

9. Sanjay Pandurang Gawade (2 out of 2 patents)

10. Dinesh Kanji Bhadra (2 out of 2 patents)

11. Devki Moje (2 out of 2 patents)

12. Pramilkumar Mathur (2 out of 2 patents)

13. Abhay Atmaram Upare (2 out of 3 patents)

14. Manmohan Nimbalkar (2 out of 3 patents)

15. Swapnali Hemant Patil (2 out of 2 patents)

17 patents: Sort by Forward Citations

1. 10105353 - Anti-thrombotic compounds (2018-10-23),

2. 9492406 - Pharmaceutical composition (2016-11-15),

3. 9321785 - Methods for the treatment or prophylaxis of thrombosis or embolism (2016-04-26),

4. 8987234 - Complex for treatment and/or prophylaxis of parasitic infections (2015-03-24),

5. 8541422 - Methods for the treatment or prophylaxis of thrombosis or embolism (2013-09-24),

6. 8536337 - Solid forms of methyl (7aS,2'S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate (2013-09-17),

7. 8415360 - Pharmaceutical compositions for the treatment of diabetes mellitus (2013-04-09),

8. 7847127 - Process for preparation of atovaquone and novel intermediates thereof (2010-12-07),

9. 7847094 - Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine (2010-12-07),

10. 7763748 - Process for preparation of highly pure isotretinoin (2010-07-27),

11. 7629465 - Industrial process for preparation of Clopidogrel hydrogen sulphate (2009-12-08),

12. 7615571 - Process for manufacture of pure (2S, 3aS, 7aS)-1-[(2S)-2-[[(1S)-1-(ethoxycarbonyl) butyl]amino]-1-oxopropyl] octahydro-1H-indole-2-carboxylic acid and its tert. butyl amine salt (2009-11-10),

13. 7547791 - One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O (2009-06-16),

14. 7459467 - Manufacturing process for methyl phenidate and intermediates thereof (2008-12-02),

15. 7414151 - Process for manufacture of 4-amino-hydroxybutylidene-1, 1-bisphosphonic acid and its salts (2008-08-19),

Company Overview

Ipca Laboratories Limited is a prominent Indian pharmaceutical company headquartered in Mumbai, specializing in the development and manufacturing of a wide range of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company focuses on various therapeutic areas, including cardiovascular, anti-infective, and pain management, among others. With a commitment to quality and innovation, Ipca serves both domestic and international markets, contributing significantly to the global healthcare landscape.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

17 Patents

#24 in Mumbai

#113 in India

#35,948 in the World

Ipca Laboratories Limited

Forward Citations = 11

49 inventors:

Ashok Kumar (16 out of 17 patents)

Dharmendra Singh (7 out of 7 patents)

Satish Rajanikant Soudagar (5 out of 6 patents)

4. Nellithanath Thankachen Byju (5 out of 5 patents)

5. Gaurav Sahal (3 out of 3 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ipca Laboratories Limited. Retrieved from https://idiyas.com/company/ipca-laboratories

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…